This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the agency's Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $306,278 to the Aohbio Corporation to discover and develop a novel small molecule therapeutic for the treatment of vitiligo. The research aims to: (1) determine the ability of the lead compound COB-187 to attenuate interferon-gamma induced cytokine expression by human keratinocytes, and (2) elucidate the mechanism by which COB-187 inhibits the expression of the cytokine CXCL10 in keratinocytes. Successful completion of this 1-year project, which commenced on September 10, 2024, is expected to provide a strong scientific foundation for the development of new therapeutics to address the significant unmet need for effective and affordable treatments for the over 2 million Americans affected by vitiligo.
Generated 3/4/25, 8:25 AM